文献速递创伤与烧伤重症综合管理与镇静镇痛

创伤患者药物性静脉血栓栓塞预防启动时机与结局的关系

Association of timing of initiation of pharmacologic venous thromboembolism prophylaxis with outcomes in trauma patients.
PubMed 文献 · J Trauma Acute Care Surg · 2021-01-01
一句话结论稳定创伤患者早期(0至<24小时)启动药物性VTE预防与较低的VTE事件风险相关。

该研究分析34个美国外科医师学会创伤委员会认证的I级和II级创伤中心的数据,纳入79,386例创伤患者,按药物性VTE预防启动时机分为0至<24小时、24至<48小时、≥48小时三组。调整预防药物类型和患者因素后,与0至<24小时组相比,24至<48小时组VTE事件风险显著增加(OR 1.26,95%CI 1.09-1.47,P=0.002),≥48小时组风险更高(OR 2.35,95%CI 2.04-2.70,P<0.001)。排除推测较高危患者后的敏感性分析中,这些VTE事件结果仍显著。结论认为稳定创伤患者早期启动药物性VTE预防与较低的VTE发生率相关。

要点

  • 在79,386例创伤患者中,1,495例(1.9%)发生VTE并发症,1,437例(1.8%)死亡。
  • 与0至<24小时启动相比,24至<48小时启动VTE预防的VTE事件OR为1.26(95%CI 1.09-1.47,P=0.002)。
  • 与0至<24小时启动相比,≥48小时启动VTE预防的VTE事件OR为2.35(95%CI 2.04-2.70,P<0.001)。
  • 排除最初4小时内输血和/或严重创伤性脑损伤患者后,VTE事件结果仍显著。
  • 稳定创伤患者早期启动药物性VTE预防与较低的VTE发生率相关。

适用人群与场景

  • 来自34个美国外科医师学会创伤委员会认证的I级和II级创伤中心的创伤患者。
  • 排除受伤时正在接受抗凝治疗、住院时间<48小时、未接受或接受非标准药物性VTE预防(肝素滴注)的患者。

研究设计与关键结果

  • 研究类型为创伤质量协作数据分析,纳入79,386例患者,按VTE预防启动时机分为0至<24小时、24至<48小时、≥48小时三组。
  • 主要终点VTE事件:1,495例(1.9%)发生VTE并发症;1,437例(1.8%)死亡。
  • 调整预防药物类型和患者因素后,与0至<24小时组相比,24至<48小时组VTE事件OR 1.26(95%CI 1.09-1.47,P=0.002),≥48小时组OR 2.35(95%CI 2.04-2.70,P<0.001)。
  • 敏感性分析排除最初4小时内输血和/或严重创伤性脑损伤患者后,VTE事件结果仍显著。

证据类型、等级与局限

  • 证据类型:创伤质量协作数据分析(诊断性研究),证据等级III级。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,稳定创伤患者早期启动药物性VTE预防与较低的VTE发生率相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Patients are at a high risk for developing venous thromboembolism (VTE) following traumatic injury. We examined the relationship between timing of initiation of pharmacologic prophylaxis with VTE complications.

METHODS: Trauma quality collaborative data from 34 American College of Surgeons Committee on Trauma-verified levels I and II trauma centers were analyzed. Patients were excluded if they were on anticoagulant therapy at the time of injury, had hospitalization <48 hours, or received no or nonstandard pharmacologic VTE prophylaxis (heparin drip). Patient comparison groups were based on timing of initiation of VTE prophylaxis relative to hospital presentation (0 to <24 hours, 24 to <48 hours, ≥48 hours). Risk-adjusted rates of VTE events were calculated accounting for patient factors including type of pharmacologic agent in addition to standard trauma patient confounders. A sensitivity analysis was performed excluding patients who received blood in the first 4 hours and/or patients with a significant traumatic brain injury.

RESULTS: Within the 79,386 patients analyzed, there were 1,495 (1.9%) who experienced a VTE complication and 1,437 (1.8%) who died. After adjusting for type of prophylaxis and patient factors, the risk of a VTE event was significantly increased in the 24- to <48-hour (odds ratio, 1.26; 95% confidence interval, 1.09-1.47; p = 0.002) and ≥48-hour (odds ratio, 2.35; 95% confidence interval, 2.04-2.70; p < 0.001) cohorts relative to patients initiated at 0 to <24 hours. These VTE event findings remained significant after exclusion of perceived higher-risk patients in a sensitivity analysis.

CONCLUSION: Early initiation of pharmacologic VTE prophylaxis in stable trauma patients is associated with lower rates of VTE.

LEVEL OF EVIDENCE: Diagnostic, level III.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Hecht JP, Han EJ, Cain-Nielsen AH, et al. Association of timing of initiation of pharmacologic venous thromboembolism prophylaxis with outcomes in trauma patients. J Trauma Acute Care Surg. 2021. PMID: 32890341. doi:10.1097/TA.0000000000002912

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。